These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21491176)

  • 1. Toxoplasmic encephalitis in AIDS-patients before and after the introduction of highly active antiretroviral therapy (HAART).
    Kiderlen TR; Liesenfeld O; Schürmann D; Schneider T
    Eur J Clin Microbiol Infect Dis; 2011 Dec; 30(12):1521-5. PubMed ID: 21491176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxoplasmic encephalitis relapse rates with pyrimethamine-based therapy: systematic review and meta-analysis.
    Connolly MP; Goodwin E; Schey C; Zummo J
    Pathog Glob Health; 2017 Feb; 111(1):31-44. PubMed ID: 28090819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings).
    Dedicoat M; Livesley N
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005420. PubMed ID: 16856096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy.
    Antinori A; Larussa D; Cingolani A; Lorenzini P; Bossolasco S; Finazzi MG; Bongiovanni M; Guaraldi G; Grisetti S; Vigo B; Gigli B; Mariano A; Dalle Nogare ER; De Marco M; Moretti F; Corsi P; Abrescia N; Rellecati P; Castagna A; Mussini C; Ammassari A; Cinque P; d'Arminio Monforte A;
    Clin Infect Dis; 2004 Dec; 39(11):1681-91. PubMed ID: 15578371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Epidemiologic characteristics of cerebral toxoplasmosis in 399 HIV-infected patients followed between 1983 and 1994].
    Bossi P; Caumes E; Astagneau P; Li TS; Paris L; Mengual X; Katlama C; Bricaire F
    Rev Med Interne; 1998 May; 19(5):313-7. PubMed ID: 9775164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxoplasmic encephalitis in an AIDS cohort at Puerto Rico before and after highly active antiretroviral therapy (HAART).
    Mayor AM; Fernández Santos DM; Dworkin MS; Ríos-Olivares E; Hunter-Mellado RF
    Am J Trop Med Hyg; 2011 May; 84(5):838-41. PubMed ID: 21540399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group.
    Podzamczer D; Miró JM; Ferrer E; Gatell JM; Ramón JM; Ribera E; Sirera G; Cruceta A; Knobel H; Domingo P; Polo R; Leyes M; Cosin J; Fariñas MC; Arrizabalaga J; Martínez-Lacasa J; Gudiol F
    Eur J Clin Microbiol Infect Dis; 2000 Feb; 19(2):89-95. PubMed ID: 10746493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
    Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
    J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ophthalmic manifestations of HIV in the highly active anti-retroviral therapy era.
    Mowatt L
    West Indian Med J; 2013; 62(4):305-12. PubMed ID: 24756590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of T-cell subsets and their relationship with oral and systemic opportunistic infections in HIV/AIDS patients during the first year of HAART in Guangxi, China.
    Zhang L; Huang Y; Liu Z; Liu W; Qin Q; Tao R
    J Med Virol; 2015 Jul; 87(7):1158-67. PubMed ID: 25777553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era.
    Abgrall S; Rabaud C; Costagliola D;
    Clin Infect Dis; 2001 Nov; 33(10):1747-55. PubMed ID: 11595976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxoplasmosis in HIV/AIDS patients: a current situation.
    Nissapatorn V; Lee C; Quek KF; Leong CL; Mahmud R; Abdullah KA
    Jpn J Infect Dis; 2004 Aug; 57(4):160-5. PubMed ID: 15329448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study.
    Matinella A; Lanzafame M; Bonometti MA; Gajofatto A; Concia E; Vento S; Monaco S; Ferrari S
    J Neurol; 2015 May; 262(5):1317-27. PubMed ID: 25877836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical presentation and outcome of toxoplasmic encephalitis in patients with human immunodeficiency virus type 1 infection.
    Ho YC; Sun HY; Chen MY; Hsieh SM; Sheng WH; Chang SC
    J Microbiol Immunol Infect; 2008 Oct; 41(5):386-92. PubMed ID: 19122919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunistic infections occurring during highly active antiretroviral treatment.
    Michelet C; Arvieux C; François C; Besnier JM; Rogez JP; Breux JP; Souala F; Allavena C; Raffi F; Garre M; Cartier F
    AIDS; 1998 Oct; 12(14):1815-22. PubMed ID: 9792382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy.
    Schmidt-Westhausen AM; Priepke F; Bergmann FJ; Reichart PA
    J Oral Pathol Med; 2000 Aug; 29(7):336-41. PubMed ID: 10947250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group.
    Podzamczer D; Miró JM; Bolao F; Gatell JM; Cosín J; Sirera G; Domingo P; Laguna F; Santamaría J; Verdejo J
    Ann Intern Med; 1995 Aug; 123(3):175-80. PubMed ID: 7598298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire.
    Losina E; Yazdanpanah Y; Deuffic-Burban S; Wang B; Wolf LL; Messou E; Gabillard D; Seyler C; Freedberg KA; Anglaret X
    Antivir Ther; 2007; 12(4):543-51. PubMed ID: 17668563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term course and outcome in AIDS patients with cerebral toxoplasmosis.
    Arendt G; von Giesen HJ; Hefter H; Neuen-Jacob E; Roick H; Jablonowski H
    Acta Neurol Scand; 1999 Sep; 100(3):178-84. PubMed ID: 10478582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.